Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT03469557
- Locations
- 🇨🇳
Fifth Medical Center of Pla General Hospital, Beijing, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
- Conditions
- Stage III Cervical CancerStage IVA Cervical CancerCervical Adenosquamous Cell CarcinomaCervical Squamous Cell Carcinoma in SituStage IB Cervical CancerStage IIB Cervical CancerNeoplasmsStage IIA Cervical Cancer
- Interventions
- First Posted Date
- 2018-03-19
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03469531
- Locations
- 🇨🇳
Zhujiang Hospital, Guangzhou, Guangdong, China
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
- Conditions
- Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 453
- Registration Number
- NCT03456063
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Arizona Oncology, Tucson, Arizona, United States
🇺🇸The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, United States
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 257
- Registration Number
- NCT03456076
- Locations
- 🇷🇺
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺GUZ Regional clinical hospital # 1, Krasnodar, Russian Federation
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
- Conditions
- Locally Advanced Lung Cancer; Metastatic Lung Cancer
- Interventions
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 54
- Registration Number
- NCT03432598
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 797
- Registration Number
- NCT03425643
- Locations
- 🇺🇸
UPMC Hillman Cancer Centers ( Site 0041), Pittsburgh, Pennsylvania, United States
🇺🇸PPG-Oncology ( Site 0043), Fort Wayne, Indiana, United States
🇺🇸Ingalls Memorial Hospital ( Site 0044), Harvey, Illinois, United States
The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy
- Conditions
- Breast CancerChemotherapy EffectDisease-free Survival
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 200
- Registration Number
- NCT03423849
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
- Conditions
- Advanced Solid Tumours
- Interventions
- Drug: AZD9150Drug: DurvalumabDrug: CisplatinDrug: 5-FlourouracilDrug: Nab-paclitaxelDrug: CarboplatinDrug: Gemcitabine
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 76
- Registration Number
- NCT03421353
- Locations
- 🇺🇸
Research Site, Fairfax, Virginia, United States
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Conditions
- Clonal Cytopenia of Undetermined SignificanceHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin LymphomaRecurrent LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory LymphomaChronic Myelomonocytic Leukemia
- Interventions
- Dietary Supplement: Ascorbic AcidDrug: CarboplatinDrug: DecitabineDrug: CisplatinDrug: CytarabineDrug: DexamethasoneDrug: EtoposideDrug: Gemcitabine HydrochlorideProcedure: Central Venous Cannula InsertionDrug: IfosfamideOther: Laboratory Biomarker AnalysisOther: Placebo AdministrationProcedure: Portacath PlacementOther: Questionnaire AdministrationBiological: RituximabDrug: OxaliplatinProcedure: Biospecimen CollectionProcedure: Core BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: EchocardiographyProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Computed Tomography
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 80
- Registration Number
- NCT03418038
- Locations
- 🇺🇸
Mayo Clinic Health System-Eau Claire Clinic, Eau Claire, Wisconsin, United States
🇺🇸Mayo Clinic Health Systems-Mankato, Mankato, Minnesota, United States
🇺🇸Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin, United States
Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 733
- Registration Number
- NCT03413436
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.